12:00 AM
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Esbriet pirfenidone regulatory update

InterMune disclosed in its 2Q13 earnings that Ireland's Health Service Executive (HSE) granted reimbursement for Esbriet pirfenidone to treat mild to moderate idiopathic pulmonary fibrosis (IPF), effective Aug. 1. InterMune said Esbriet is...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >